- Home
- PUMP vs GYRE Comparison
PUMP vs GYRE Comparison
Compare PUMP & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PUMP
- GYRE
- Stock Information
- Founded
- PUMP 2007
- GYRE 2002
- Country
- PUMP United States
- GYRE United States
- Employees
- PUMP N/A
- GYRE N/A
- Industry
- PUMP Oilfield Services/Equipment
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- PUMP Energy
- GYRE Health Care
- Exchange
- PUMP Nasdaq
- GYRE Nasdaq
- Market Cap
- PUMP 938.7M
- GYRE 997.3M
- IPO Year
- PUMP 2017
- GYRE N/A
- Fundamental
- Price
- PUMP $9.10
- GYRE $11.54
- Analyst Decision
- PUMP Buy
- GYRE
- Analyst Count
- PUMP 7
- GYRE 0
- Target Price
- PUMP $11.17
- GYRE N/A
- AVG Volume (30 Days)
- PUMP 1.4M
- GYRE 53.5K
- Earning Date
- PUMP 02-19-2025
- GYRE 03-25-2025
- Dividend Yield
- PUMP N/A
- GYRE N/A
- EPS Growth
- PUMP N/A
- GYRE N/A
- EPS
- PUMP N/A
- GYRE N/A
- Revenue
- PUMP $1,444,286,000.00
- GYRE $105,033,000.00
- Revenue This Year
- PUMP N/A
- GYRE $25.32
- Revenue Next Year
- PUMP N/A
- GYRE $12.95
- P/E Ratio
- PUMP N/A
- GYRE N/A
- Revenue Growth
- PUMP N/A
- GYRE N/A
- 52 Week Low
- PUMP $6.54
- GYRE $8.26
- 52 Week High
- PUMP $11.17
- GYRE $26.37
- Technical
- Relative Strength Index (RSI)
- PUMP 48.05
- GYRE 47.99
- Support Level
- PUMP $8.75
- GYRE $12.09
- Resistance Level
- PUMP $9.22
- GYRE $12.80
- Average True Range (ATR)
- PUMP 0.37
- GYRE 0.56
- MACD
- PUMP 0.00
- GYRE -0.00
- Stochastic Oscillator
- PUMP 56.91
- GYRE 16.39
About PUMP ProPetro Holding Corp.
ProPetro Holding Corp is a Texas-based oilfield services company. It provides hydraulic fracturing, wireline, and other complementary services to oil and gas companies engaged in the exploration and production of North American oil and natural gas resources. The company focused on the Permian Basin. The operating segments of the company are hydraulic fracturing which generates key revenue, wireline, cementing, and coiled tubing.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.